中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
33期
11-12
,共2页
郭迪斌%娟居艳%李荣平%谷晓晶%王飙%甘凤英%陈琥
郭迪斌%娟居豔%李榮平%穀曉晶%王飆%甘鳳英%陳琥
곽적빈%연거염%리영평%곡효정%왕표%감봉영%진호
系统性红斑狼疮%肺动脉高压%临床特征%预后
繫統性紅斑狼瘡%肺動脈高壓%臨床特徵%預後
계통성홍반랑창%폐동맥고압%림상특정%예후
Systemic lupus erythematosus%Pulmonary arterial hypertension%Clinical features%Prognosis
目的:探讨系统性红斑狼疮(SLE)合并肺动脉高压(PAH)患者的临床特征以及其治疗预后。方法:选取在2008年1月-2012年4月本院风湿科收治的SLE患者64例,其中18例合并PAH患者为观察组,46例未合并PAH患者为对照组,对比两组临床特征及预后。结果:观察组心悸气促、浆膜炎、雷诺现象的发生率均明显高于对照组(P<0.05);治疗后观察组临床指标均明显优于治疗前(P<0.05),但重症SLE-PAH患者的预后较差。结论:心悸气促、浆膜炎以及雷诺现象均是SLE患者并发PAH的高危因素,对于并发PAH患者的治疗应在积极的SLE疾病治疗的基础上进行PAH的对症治疗,并尽可能的进行早期治疗,以提高治疗效果。
目的:探討繫統性紅斑狼瘡(SLE)閤併肺動脈高壓(PAH)患者的臨床特徵以及其治療預後。方法:選取在2008年1月-2012年4月本院風濕科收治的SLE患者64例,其中18例閤併PAH患者為觀察組,46例未閤併PAH患者為對照組,對比兩組臨床特徵及預後。結果:觀察組心悸氣促、漿膜炎、雷諾現象的髮生率均明顯高于對照組(P<0.05);治療後觀察組臨床指標均明顯優于治療前(P<0.05),但重癥SLE-PAH患者的預後較差。結論:心悸氣促、漿膜炎以及雷諾現象均是SLE患者併髮PAH的高危因素,對于併髮PAH患者的治療應在積極的SLE疾病治療的基礎上進行PAH的對癥治療,併儘可能的進行早期治療,以提高治療效果。
목적:탐토계통성홍반랑창(SLE)합병폐동맥고압(PAH)환자적림상특정이급기치료예후。방법:선취재2008년1월-2012년4월본원풍습과수치적SLE환자64례,기중18례합병PAH환자위관찰조,46례미합병PAH환자위대조조,대비량조림상특정급예후。결과:관찰조심계기촉、장막염、뢰낙현상적발생솔균명현고우대조조(P<0.05);치료후관찰조림상지표균명현우우치료전(P<0.05),단중증SLE-PAH환자적예후교차。결론:심계기촉、장막염이급뢰낙현상균시SLE환자병발PAH적고위인소,대우병발PAH환자적치료응재적겁적SLE질병치료적기출상진행PAH적대증치료,병진가능적진행조기치료,이제고치료효과。
Objective:To investigate pulmonary hypertension in patients with systemic lupus erythematosus clinical features as well as its treatment and prognosis.Method: 64 patients with SLE were selected in our hospital from January 2008 to April 2012, 18 cases of merger PAH as observation group, 46 cases of unincorporated PAH as control group, compared two groups of clinical features and prognosis.Result:Palpitations shortness of breath, serositis, the incidence of Raynaud’s phenomenon in observation group were significantly higher than that of control group (P<0.05); After treatment the clinical indicators of observation group were significantly better than that of before treatment (P<0.05), but the prognosis of severe SLE patients with PAH was poorer. Conclusion: Heart palpitations, shortness of breath, serositis and Renault are high risk factors of the SLE patients with PAH, for the treatment of patients with concurrent PAH should be on the basis of active SLE disease treatment for symptomatic treatment of PAH, as much as possible and early treatment, in order to improve treatment effect.